论文部分内容阅读
目的探讨水飞蓟宾联合洛伐他汀治疗非酒精性脂肪肝的临床疗效。方法 92例非酒精性脂肪肝患者,随机分为观察组和对照组,每组46例。对照组患者采用洛伐他汀进行治疗,观察组患者采用水飞蓟宾联合洛伐他汀进行治疗。比较两组患者的治疗效果。结果观察组患者的治疗总有效率为91.30%,明显高于对照组的73.91%,差异具有统计学意义(P<0.05);观察组患者的各项血脂指标均明显优于对照组,差异均具有统计学意义(P<0.05)。结论水飞蓟宾联合洛伐他汀治疗非酒精性脂肪肝的临床效果良好,值得临床推广使用。
Objective To investigate the clinical efficacy of silibinin and lovastatin in the treatment of non-alcoholic fatty liver disease. Methods 92 patients with non-alcoholic fatty liver were randomly divided into observation group and control group, 46 cases in each group. Patients in the control group were treated with lovastatin, and patients in the observation group were treated with silibinin combined with lovastatin. The treatment effect of two groups of patients was compared. Results The total effective rate of observation group was 91.30%, which was significantly higher than that of control group (73.91%), the difference was statistically significant (P <0.05). The blood lipid indexes in observation group were significantly better than those in control group Statistically significant (P <0.05). Conclusion The combination of silibinin and lovastatin has a good clinical effect in non-alcoholic fatty liver disease and is worthy of clinical promotion.